(VBK) VERBIO Vereinigte BioEnergie - Overview
Exchange: XETRA •
Country: Germany •
Currency: EUR •
Type: Common Stock •
ISIN: DE000A0JL9W6
Stock:
Total Rating 53
Risk 61
Buy Signal 0.82
| Risk 5d forecast | |
|---|---|
| Volatility | 64.7% |
| Relative Tail Risk | -12.2% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 2.12 |
| Alpha | 196.99 |
| Character TTM | |
|---|---|
| Beta | 0.715 |
| Beta Downside | 1.908 |
| Drawdowns 3y | |
|---|---|
| Max DD | 84.32% |
| CAGR/Max DD | -0.20 |
EPS (Earnings per Share)
Revenue
Description: VBK VERBIO Vereinigte BioEnergie
Verbio SE engages in the production and distribution of fuels and finished products in Germany, Europe, North America, and internationally. It operates through Biodiesel, Bioethanol/Biomethane, and Other segments. The company provides bio-based chemicals, biodiesel, pharma-glycerine, biomethane, and bioethanol; olefin metathesis catalysts; animal feeds, such as Verbio Proti Flow and Verbio Grain Pro; phytosterols under the Sterocellent brand; and fertilizers. It also offers trading, and transport and logistics services. The company's products are used for cosmetics, food, pharmaceuticals, heat and power generation, fuels, renewable chemicals, aromas and fragrances, plastics, agrochemicals, and agriculture applications. It serves oil, oil mills, pharmaceuticals, trading and logistics, transport and fleet operators, energy utilities, farmers, LNG/CNG filling stations/retail, and other industries. The company was formerly known as VERBIO Vereinigte BioEnergie AG and changed its name to Verbio SE in December 2023. Verbio SE was founded in 2006 and is based in Leipzig, Germany.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: -112.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.05 > 0.02 and ΔFCF/TA -0.55 > 1.0 |
| NWC/Revenue: 13.28% < 20% (prev 20.00%; Δ -6.72% < -1%) |
| CFO/TA 0.03 > 3% & CFO 43.3m > Net Income -112.2m |
| Net Debt (215.7m) to EBITDA (47.2m): 4.57 < 3 |
| Current Ratio: 1.75 > 1.5 & < 3 |
| Outstanding Shares: last quarter (67.6m) vs 12m ago 14.19% < -2% |
| Gross Margin: 6.98% > 18% (prev 0.16%; Δ 682.8% > 0.5%) |
| Asset Turnover: 128.8% > 50% (prev 107.5%; Δ 21.25% > 0%) |
| Interest Coverage Ratio: -4.79 > 6 (EBITDA TTM 47.2m / Interest Expense TTM 18.0m) |
Altman Z'' 1.76
| A: 0.18 (Total Current Assets 532.2m - Total Current Liabilities 303.4m) / Total Assets 1.28b |
| B: 0.15 (Retained Earnings 197.0m / Total Assets 1.28b) |
| C: -0.06 (EBIT TTM -86.4m / Avg Total Assets 1.34b) |
| D: 0.49 (Book Value of Equity 260.7m / Total Liabilities 533.3m) |
| Altman-Z'' Score: 1.76 = BBB |
Beneish M -2.40
| DSRI: 1.02 (Receivables 106.5m/91.5m, Revenue 1.72b/1.50b) |
| GMI: 2.23 (GM 6.98% / 15.55%) |
| AQI: 0.20 (AQ_t 0.00 / AQ_t-1 0.02) |
| SGI: 1.15 (Revenue 1.72b / 1.50b) |
| TATA: -0.12 (NI -112.2m - CFO 43.3m) / TA 1.28b) |
| Beneish M-Score: -2.40 (Cap -4..+1) = BBB |
What is the price of VBK shares?
As of March 01, 2026, the stock is trading at EUR 27.40 with a total of 181,335 shares traded.
Over the past week, the price has changed by +13.22%, over one month by +8.21%, over three months by +53.67% and over the past year by +207.35%.
Over the past week, the price has changed by +13.22%, over one month by +8.21%, over three months by +53.67% and over the past year by +207.35%.
Is VBK a buy, sell or hold?
VERBIO Vereinigte BioEnergie has no consensus analysts rating.
What are the forecasts/targets for the VBK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 14.7 | -46.5% |
| Analysts Target Price | - | - |
VBK Fundamental Data Overview March 01, 2026
Market Cap USD = 1.32b (1.12b EUR * 1.1832 EUR.USD)
P/S = 0.9203
P/B = 2.0862
Revenue TTM = 1.72b EUR
EBIT TTM = -86.4m EUR
EBITDA TTM = 47.2m EUR
Long Term Debt = 173.4m EUR (from longTermDebt, last quarter)
Short Term Debt = 94.9m EUR (from shortTermDebt, last quarter)
Debt = 287.2m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 215.7m EUR (from netDebt column, last quarter)
Enterprise Value = 1.32b EUR (1.12b + Debt 287.2m - CCE 86.0m)
Interest Coverage Ratio = -4.79 (Ebit TTM -86.4m / Interest Expense TTM 18.0m)
EV/FCF = -18.78x (Enterprise Value 1.32b / FCF TTM -70.1m)
FCF Yield = -5.33% (FCF TTM -70.1m / Enterprise Value 1.32b)
FCF Margin = -4.07% (FCF TTM -70.1m / Revenue TTM 1.72b)
Net Margin = -6.52% (Net Income TTM -112.2m / Revenue TTM 1.72b)
Gross Margin = 6.98% ((Revenue TTM 1.72b - Cost of Revenue TTM 1.60b) / Revenue TTM)
Gross Margin QoQ = 17.38% (prev 13.21%)
Tobins Q-Ratio = 1.03 (Enterprise Value 1.32b / Total Assets 1.28b)
Interest Expense / Debt = 0.80% (Interest Expense 2.30m / Debt 287.2m)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = -64.8m (EBIT -86.4m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 1.75 (Total Current Assets 532.2m / Total Current Liabilities 303.4m)
Debt / Equity = 0.39 (Debt 287.2m / totalStockholderEquity, last quarter 742.8m)
Debt / EBITDA = 4.57 (Net Debt 215.7m / EBITDA 47.2m)
Debt / FCF = -3.08 (negative FCF - burning cash) (Net Debt 215.7m / FCF TTM -70.1m)
Total Stockholder Equity = 776.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -8.39% (Net Income -112.2m / Total Assets 1.28b)
RoE = -14.46% (Net Income TTM -112.2m / Total Stockholder Equity 776.0m)
RoCE = -9.10% (EBIT -86.4m / Capital Employed (Equity 776.0m + L.T.Debt 173.4m))
RoIC = -6.29% (negative operating profit) (NOPAT -64.8m / Invested Capital 1.03b)
WACC = 6.92% (E(1.12b)/V(1.40b) * Re(8.55%) + D(287.2m)/V(1.40b) * Rd(0.80%) * (1-Tc(0.25)))
Discount Rate = 8.55% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -8.32%
[DCF] Fair Price = unknown (Cash Flow -70.1m)
EPS Correlation: -87.58 | EPS CAGR: -17.58% | SUE: -0.10 | # QB: 0
Revenue Correlation: -52.22 | Revenue CAGR: 1.65% | SUE: 1.76 | # QB: 1
EPS current Year (2026-06-30): EPS=0.07 | Chg7d=+0.027 | Chg30d=+0.027 | Revisions Net=-1 | Growth EPS=+103.2% | Growth Revenue=+11.2%
EPS next Year (2027-06-30): EPS=0.74 | Chg7d=-0.005 | Chg30d=-0.052 | Revisions Net=-3 | Growth EPS=+969.0% | Growth Revenue=+13.0%
P/S = 0.9203
P/B = 2.0862
Revenue TTM = 1.72b EUR
EBIT TTM = -86.4m EUR
EBITDA TTM = 47.2m EUR
Long Term Debt = 173.4m EUR (from longTermDebt, last quarter)
Short Term Debt = 94.9m EUR (from shortTermDebt, last quarter)
Debt = 287.2m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 215.7m EUR (from netDebt column, last quarter)
Enterprise Value = 1.32b EUR (1.12b + Debt 287.2m - CCE 86.0m)
Interest Coverage Ratio = -4.79 (Ebit TTM -86.4m / Interest Expense TTM 18.0m)
EV/FCF = -18.78x (Enterprise Value 1.32b / FCF TTM -70.1m)
FCF Yield = -5.33% (FCF TTM -70.1m / Enterprise Value 1.32b)
FCF Margin = -4.07% (FCF TTM -70.1m / Revenue TTM 1.72b)
Net Margin = -6.52% (Net Income TTM -112.2m / Revenue TTM 1.72b)
Gross Margin = 6.98% ((Revenue TTM 1.72b - Cost of Revenue TTM 1.60b) / Revenue TTM)
Gross Margin QoQ = 17.38% (prev 13.21%)
Tobins Q-Ratio = 1.03 (Enterprise Value 1.32b / Total Assets 1.28b)
Interest Expense / Debt = 0.80% (Interest Expense 2.30m / Debt 287.2m)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = -64.8m (EBIT -86.4m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 1.75 (Total Current Assets 532.2m / Total Current Liabilities 303.4m)
Debt / Equity = 0.39 (Debt 287.2m / totalStockholderEquity, last quarter 742.8m)
Debt / EBITDA = 4.57 (Net Debt 215.7m / EBITDA 47.2m)
Debt / FCF = -3.08 (negative FCF - burning cash) (Net Debt 215.7m / FCF TTM -70.1m)
Total Stockholder Equity = 776.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -8.39% (Net Income -112.2m / Total Assets 1.28b)
RoE = -14.46% (Net Income TTM -112.2m / Total Stockholder Equity 776.0m)
RoCE = -9.10% (EBIT -86.4m / Capital Employed (Equity 776.0m + L.T.Debt 173.4m))
RoIC = -6.29% (negative operating profit) (NOPAT -64.8m / Invested Capital 1.03b)
WACC = 6.92% (E(1.12b)/V(1.40b) * Re(8.55%) + D(287.2m)/V(1.40b) * Rd(0.80%) * (1-Tc(0.25)))
Discount Rate = 8.55% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -8.32%
[DCF] Fair Price = unknown (Cash Flow -70.1m)
EPS Correlation: -87.58 | EPS CAGR: -17.58% | SUE: -0.10 | # QB: 0
Revenue Correlation: -52.22 | Revenue CAGR: 1.65% | SUE: 1.76 | # QB: 1
EPS current Year (2026-06-30): EPS=0.07 | Chg7d=+0.027 | Chg30d=+0.027 | Revisions Net=-1 | Growth EPS=+103.2% | Growth Revenue=+11.2%
EPS next Year (2027-06-30): EPS=0.74 | Chg7d=-0.005 | Chg30d=-0.052 | Revisions Net=-3 | Growth EPS=+969.0% | Growth Revenue=+13.0%